[China Biologic Opens Plasma Collection Station in Hebei Province BEIJING, China – June 20, 2016 – The Company received approval to build two new plasma collection stations in Xinglong and Daming Counties, respectively, in October 2014. The new Xinglong station covers a collection territory of approximately 0.4 million people. The Company expects the new station to reach its designed annual] []
[China Biologic Opens Plasma Collection Station in Hebei Province BEIJING, China – June 20, 2016 – The Company received approval to build two new plasma collection stations in Xinglong and Daming Counties, respectively, in October 2014. The new Xinglong station covers a collection territory of approximately 0.4 million people. The Company expects the new station to reach its designed annual] []
[CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]
[CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]
[7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June 2, 2016 (To Prospectus dated June 5, 2015) 2,775,000 Shares China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 2,775,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
[7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June 2, 2016 (To Prospectus dated June 5, 2015) 2,775,000 Shares China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 2,775,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [June 6, 2016 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Shares Selling Stockholders Underwriting Agreement We understand that 2,775,000 shares of Common Stock (the “ As legal counsel to] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – June 2, 2016 The shares to be sold in this offering represent approximately 10.4 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] []
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [June 6, 2016 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Shares Selling Stockholders Underwriting Agreement We understand that 2,775,000 shares of Common Stock (the “ As legal counsel to] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – June 2, 2016 The shares to be sold in this offering represent approximately 10.4 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] []
